GlassScriptPhysician profile
Judy Joseph
NPI 1346294642
$3,763.22
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,181 · 2020: $901 · 2021: $666 · 2022: $15.48.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $707.40 | 2019-2021 | |
| Glaxosmithkline, LLC. | $635.63 | 2019-2021 | |
| Pfizer INC. | $485.19 | 2019-2021 | |
| Novo Nordisk INC | $349.82 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $342.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $203.15 | 2019-2021 | |
| Mylan Specialty L.P. | $188.15 | 2019-2021 | |
| Lilly USA, LLC | $147.33 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.45 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.72 | 2019-2021 | |
| Allergan, INC. | $96.89 | 2019 | |
| Ironwood Pharmaceuticals, INC | $58.02 | 2019-2020 | |
| Smith+Nephew, INC. | $41.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $30.69 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.73 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $23.81 | 2020 | |
| Amgen INC. | $23.22 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $21.02 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.90 | 2020 | |
| Astellas Pharma US INC | $19.49 | 2019 | |
| Genzyme Corporation | $13.91 | 2019 | |
| Dexcom, INC. | $13.43 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.29 | 2019 | |
| Amarin Pharma, INC. | $10.99 | 2019 |
Research and ownership
$644.51 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judy Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.